|
Real-time Estimate
Cboe Europe
04:14:00 2026-09-07 am EDT
|
5-day change | 1st Jan Change | ||
| 1,834.00 GBX | -0.68% |
|
-2.06% | +0.47% |
| Sep. 03 | Global markets live: Apple, Microsoft, Tesla, Google, Uber… |  |
| Sep. 03 | Haleon Negotiates Better Shelf Placement at Walmart, Target | MT |
| Market Cap | 73.99B 100B 86.09B 81B 138B 9,446B 139B 957B 371B 4,846B 376B 367B 15,612B | P/E 2026 * |
14x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 93.83B 127B 109B 103B 176B 11,978B 176B 1,214B 471B 6,146B 476B 466B 19,798B | EV / Sales 2026 * |
2.77x | EV / Sales 2027 * | 2.57x |
| Free-Float |
92.75% | Yield 2026 * |
3.77% | Yield 2027 * | 4.06% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
OTC Markets
| GLAXF | Delayed | |
|
Deutsche Boerse AG
| GS71 | Delayed | |
|
Börse Stuttgart
| GS71 | Delayed |
Last Transcript : GSK plc
| Sep. 03 | Wall Street's Triple Squeeze | |
| Sep. 02 | GSK plc : Deutsche Bank reiterates its Neutral rating | ZD |
| Sep. 01 | GSK plc : JP Morgan gives a Sell rating | ZD |
| Aug. 25 | GSK plc : Deutsche Bank remains Neutral | ZD |
| Aug. 20 | Cancer vaccines finally garner the spotlight |  |
| 1 day | -0.70% | ||
| 1 week | -1.92% | ||
| Current month | -0.96% | ||
| 1 month | -6.37% | ||
| 3 months | -4.04% | ||
| 6 months | -10.28% | ||
| Current year | +0.61% |
| 1 week | 1,825.5 |  | 1,911 |
| 1 month | 1,803 | | 1,972 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,445 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/24/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 8/21/26 | Sell | Executive/Senior Manager | -28,978 | 0.0007% | ||
| 8/21/26 | Sell | Executive/Senior Manager | -49 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.70% | -1.92% | +25.34% | +32.23% | 100B | |
| -0.88% | -2.15% | +58.05% | +105.26% | 1,024B | |
| -1.15% | +2.68% | +54.25% | +74.19% | 663B | |
| -1.44% | +0.38% | +20.65% | +76.13% | 453B | |
| -1.44% | -0.06% | +30.54% | +37.39% | 352B | |
| -3.63% | +1.67% | +22.48% | +41.40% | 304B | |
| +0.45% | +0.99% | +0.92% | +11.60% | 252B | |
| -1.55% | +1.11% | +54.15% | +75.59% | 236B | |
| -0.64% | +1.54% | -14.43% | -56.10% | 206B | |
| -0.15% | +3.65% | +31.24% | +103.39% | 187B | |
| Average | -1.10% | +1.10% | +28.32% | +50.11% | 377.84B | |
| Weighted average by Cap. | -1.16% | +0.59% | +37.28% | +65.94% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.93B 45.88B 39.48B 37.15B 63.48B 4,332B 63.65B 439B 170B 2,223B 172B 169B 7,160B | 35.49B 47.99B 41.29B 38.85B 66.39B 4,531B 66.57B 459B 178B 2,325B 180B 176B 7,489B |
| Net income | 5.42B 7.33B 6.31B 5.94B 10.14B 692B 10.17B 70.14B 27.22B 355B 27.53B 26.93B 1,144B | 6.47B 8.75B 7.53B 7.08B 12.1B 826B 12.13B 83.67B 32.47B 424B 32.84B 32.12B 1,365B |
| Net Debt | 19.84B 26.82B 23.08B 21.72B 37.11B 2,533B 37.21B 257B 99.58B 1,299B 101B 98.53B 4,186B | 17.06B 23.07B 19.85B 18.68B 31.91B 2,178B 32B 221B 85.63B 1,117B 86.62B 84.73B 3,600B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-07 | GBX 1,833.50 | -0.70% | 140,668 |
| 26-09-04 | GBX 1,846.50 | -1.07% | 3,782,887 |
| 26-09-03 | GBX 1,866.50 | +0.27% | 4,089,944 |
| 26-09-02 | GBX 1,861.50 | -0.53% | 4,977,854 |
| 26-09-01 | GBX 1,871.50 | +0.97% | 4,720,553 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
